Sanofi (NASDAQ:SNY) Upgraded by Wall Street Zen to Strong-Buy Rating

Wall Street Zen upgraded shares of Sanofi (NASDAQ:SNY) from a buy rating to a strong-buy rating in a research note issued to investors on Saturday morning.

SNY has been the subject of a number of other reports. Guggenheim lowered shares of Sanofi from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 9th. Barclays cut shares of Sanofi from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, January 6th. Citigroup started coverage on shares of Sanofi in a report on Tuesday. They set a “neutral” rating on the stock. Jefferies Financial Group reissued a “buy” rating on shares of Sanofi in a research note on Monday, October 27th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Sanofi in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $62.67.

Sanofi Stock Up 1.8%

Shares of NASDAQ SNY opened at $47.04 on Friday. Sanofi has a 52-week low of $44.62 and a 52-week high of $60.12. The firm has a market capitalization of $114.73 billion, a price-to-earnings ratio of 13.07, a PEG ratio of 1.34 and a beta of 0.45. The stock has a 50 day moving average price of $48.13 and a 200 day moving average price of $48.69. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.30 and a current ratio of 1.06.

Hedge Funds Weigh In On Sanofi

Large investors have recently made changes to their positions in the business. Flagship Harbor Advisors LLC purchased a new position in Sanofi during the 4th quarter worth $25,000. Financial Consulate Inc. acquired a new stake in Sanofi in the third quarter worth about $26,000. Ameritas Advisory Services LLC purchased a new stake in shares of Sanofi during the second quarter worth about $28,000. Measured Wealth Private Client Group LLC purchased a new stake in shares of Sanofi during the third quarter worth about $29,000. Finally, Palisade Asset Management LLC acquired a new position in shares of Sanofi during the third quarter valued at about $30,000. 14.03% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Sanofi

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Q4 beat: Sanofi reported adjusted EPS and revenue above consensus, driven by cost control and 7% revenue growth — a clean earnings beat that supports upside to profits. Sanofi Beats on Q4 Earnings, Expects Profitable Growth in 2026
• Positive Sentiment: Dupixent outperformance: Strong demand for Dupixent helped lift revenue and beat forecasts, underpinning management’s bullish commentary for 2026 and reducing near-term execution risk. Sanofi edges higher as immunology powerhouse, Dupixent, wallops forecasts
• Positive Sentiment: CHMP positive opinion for Rezurock: The EMA’s CHMP recommended conditional EU approval of Rezurock (belumosudil) for chronic graft‑versus‑host disease (adults and ≥12y/≥40kg kids) — if approved this expands Sanofi’s late‑line immunology/hematology portfolio and adds a new EU revenue stream. Press Release: Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease
• Positive Sentiment: Share buyback: Sanofi announced a $1.20B share repurchase program, a direct capital return that supports EPS and signals confidence in cash generation. Sanofi to Launch $1.20 Billion Share Buyback
• Neutral Sentiment: 2026 outlook: Management targets high single‑digit sales growth for 2026 — a reasonable growth guide that is supportive but not transformative; investors will judge execution vs. that target. Sanofi targets high single-digit sales growth 2026, plans share buyback
• Neutral Sentiment: Market reception mixed: Media coverage notes the earnings and pipeline updates “matched expectations” in some outlets, producing only modest stock movement despite the positives — suggests investors are balancing beat vs. broader sector concerns. Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite
• Negative Sentiment: Ongoing risk: Commentary referenced the pharma “patent cliff” and the need for pipeline replacements — a reminder that sustained outperformance depends on continued launches and lifecycle management. Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.